Carnegie Investment Counsel Sells 894 Shares of Eli Lilly and Company $LLY

Carnegie Investment Counsel reduced its position in Eli Lilly and Company (NYSE:LLY) by 7.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,540 shares of the company’s stock after selling 894 shares during the quarter. Carnegie Investment Counsel’s holdings in Eli Lilly and Company were worth $12,402,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Brighton Jones LLC lifted its holdings in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after acquiring an additional 1,730 shares during the period. Revolve Wealth Partners LLC lifted its holdings in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock valued at $1,136,000 after acquiring an additional 40 shares during the period. Schnieders Capital Management LLC. lifted its holdings in shares of Eli Lilly and Company by 16.7% during the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares during the period. Flow Traders U.S. LLC bought a new position in shares of Eli Lilly and Company during the second quarter valued at $356,000. Finally, Nebula Research & Development LLC bought a new position in shares of Eli Lilly and Company during the second quarter valued at $749,000. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Scotiabank reissued an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. BMO Capital Markets reissued an “outperform” rating and set a $1,300.00 price objective on shares of Eli Lilly and Company in a report on Thursday, February 5th. Leerink Partners lifted their price objective on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a report on Thursday, February 5th. Cantor Fitzgerald lifted their price objective on Eli Lilly and Company from $985.00 to $1,205.00 and gave the company an “overweight” rating in a report on Thursday, February 5th. Finally, Wall Street Zen cut Eli Lilly and Company from a “strong-buy” rating to a “buy” rating in a report on Monday, April 6th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,224.59.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Jaypirca (pirtobrutinib) posted positive Phase 3 BRUIN CLL‑322 results showing significantly extended progression‑free survival when added to venetoclax + rituximab — a fourth positive Phase 3 readout that meaningfully strengthens Lilly’s oncology franchise and potential label expansion. PR Newswire: Jaypirca Phase 3
• Positive Sentiment: Lilly acquired preclinical ADC specialist CrossBridge in a roughly $300M deal, adding antibody‑drug conjugate expertise to its oncology pipeline — an inorganic move that accelerates biologics/ADC capabilities. FierceBiotech: CrossBridge acquisition
• Positive Sentiment: Lilly expanded external AI ties by enabling Vasa Therapeutics to use Lilly’s TuneLab AI/ML drug‑discovery models — this monetizes Lilly’s platform and can accelerate external partnerships and milestone revenue. Yahoo Finance: Vasa / TuneLab
• Positive Sentiment: Regulatory approval of Foundayo (Lilly’s oral GLP‑1 weight‑loss pill) continues to underpin the company’s blockbuster growth narrative and long‑term revenue trajectory in obesity care. The Motley Fool: Foundayo approval
• Neutral Sentiment: Media speculation about a long‑term bull case (e.g., a Forbes piece arguing LLY could reach $2,000) boosts narrative optimism but is highly model‑dependent and not new fundamental news. Forbes: LLY $2,000 thesis
• Neutral Sentiment: Analyst price‑target activity is mixed — outlets show fresh raises (to $880 and to $1,327), highlighting divergent views on near‑term valuation vs. long‑term growth. Investors should note wide target dispersion. American Banking News: PT $880 American Banking News: PT $1,327
• Negative Sentiment: Competitive risk: Novo Nordisk’s new partnership with OpenAI to speed drug development underscores intensifying AI‑driven competition in the obesity/GLP‑1 space, which could pressure market share and future growth assumptions for Lilly. Pharmaceutical-Technology: Novo + OpenAI

Eli Lilly and Company Price Performance

Eli Lilly and Company stock opened at $922.83 on Wednesday. The firm has a market capitalization of $871.91 billion, a P/E ratio of 40.21, a PEG ratio of 1.08 and a beta of 0.51. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $1,133.95. The business has a 50-day moving average of $980.12 and a 200-day moving average of $980.41. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The company had revenue of $19.29 billion during the quarter, compared to analyst estimates of $17.85 billion. During the same period in the previous year, the company earned $5.32 EPS. The company’s revenue for the quarter was up 42.6% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.